Home/Filings/4/0001193125-25-183434
4//SEC Filing

Young Teresa L. 4

Accession 0001193125-25-183434

CIK 0001609809other

Filed

Aug 18, 8:00 PM ET

Accepted

Aug 19, 4:06 PM ET

Size

12.4 KB

Accession

0001193125-25-183434

Insider Transaction Report

Form 4
Period: 2025-08-15
Young Teresa L.
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2025-08-15+1335,177 total
  • Sale

    Common Stock

    2025-08-18$16.65/sh59$9825,215 total
  • Exercise/Conversion

    Common Stock

    2025-08-15+975,274 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-08-15133796 total
    Common Stock (133 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-08-1597976 total
    Common Stock (97 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  • [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Documents

1 file

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001814656

Filing Metadata

Form type
4
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 4:06 PM ET
Size
12.4 KB